Why Is HEMAB THERAPEUTICS H (COAG) Stock Down Today?

COAG stock fell 5.77% to $51.77 in afternoon trading on Friday. The decline came despite a recent price target increase from Wedbush and other positive analyst coverage. The stock opened with a 3.2% gap up from the previous close but reversed sharply throughout the session, reaching a low of $51.77.

What Happened

Hemab Therapeutics opened at $56.70, reflecting a positive gap from the prior close of $54.94. However, the stock quickly reversed course and declined throughout the day, closing at $51.77 at 2:05 PM ET. The session saw a volume of 0.1M shares, below the average for the stock. The move followed Wedbush’s recent upgrade of the price target to $64 from $55 and similar upgrades from HC Wainwright & Co. and Jefferies. Despite this analyst activity, the stock’s performance was weighed down by the company’s Q2 earnings report, which showed an EPS of $(0.80), missing the estimated $(0.52). Hemab also announced the presentation of clinical and preclinical data at the International Society on Thrombosis and Haemostasis 2026 Congress.

What The Data Shows

The stock has traded between $23.00 and $55.42 over the past 52 weeks. The recent intraday move saw the stock print two fresh 52-week highs and two fresh 52-week lows on August 17. Insider transactions show Ra Capital Management, L.P. has made two purchases totaling $1.8M in the past 90 days, with the most recent filing on June 17. These transactions suggest continued confidence from major stakeholders.

What To Watch

Investors should monitor the stock ahead of any upcoming corporate developments or additional analyst commentary. No earnings date was provided in the data. Coverage breadth and price target changes from key analysts will remain important to watch.